Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant FGFR2/3

Structures

FGFR2 Kinase Domain in Complex with a Pyrazolo[1,5-a]pyrimidine Analog

Potent Dual Inhibition: Compound 29 retains low-nanomolar potency against wild-type and gatekeeper FGFR2/3, with excellent ADME and PK profiles.
PROTAC Strategy: Selective FGFR2 degrader 28e achieves DC₅₀ = 0.645 nM, sparing FGFR1/3/4 and overcoming V564F resistance.
AI-Driven Design: Generative chemistry engines identify novel cores enabling high FGFR2/3 selectivity and in vivo efficacy.
Dynamics-Based Selectivity: Lirafugratinib (RLY-4008) exploits protein motion to distinguish FGFR2 from FGFR1, showing 73% clinical response and reduced hyperphosphatemia.
Irreversible Covalent Inhibition: BW710 covalently binds FGFR2 with high potency and oral bioavailability, sparing other FGFRs.
Precision Oncology Impact: Selective FGFR2/3 inhibitors promise durable responses with improved safety profiles.

Artem Shvartsbart, et.al., ACS J. Med. Chem
Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitor: Zuli Hu, et.al., Eur. J. Med. Chem
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Carcinoma: Yoshikazu Nakaki, et.al., J. Med. Chem
Discovery of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor: Lakshmi N. Palaniappan, et.al., PNAS
Discovery of BW710 as a potent, selective and orally bioavailable FGFR2 inhibitor: Yalan Xie, et.al., Eur. J. Med. Chem
Insilico Medicine publishes AI-driven innovative design strategy for highly selective FGFR2/3 inhibitors: Insilico Medicine, et.al., J. Med. Chem

The fibroblast growth factor receptor (FGFR) family, particularly FGFR2 and FGFR3, plays a crucial role in cellular growth and survival, with aberrant activation implicated in cancers such as cholangiocarcinoma and bladder cancer. First-generation pan-FGFR inhibitors, while effective, often cause hyperphosphatemia and lose potency against gatekeeper mutations. This study describes the rational design and optimization of a new class of FGFR2/3 inhibitors that maintain high potency against both wild-type and gatekeeper mutant forms, while exhibiting strong selectivity over FGFR1 and other kinases. Key advances included structure-based drug design, strategic modifications to the inhibitor scaffold, and careful tuning of pharmacokinetic properties, leading to the identification of compound 29. This molecule demonstrated sub-nanomolar potency for FGFR2/3, excellent selectivity, favorable ADME properties, and robust oral bioavailability in preclinical models. Importantly, the new inhibitors avoid the reliance on interactions that are compromised by gatekeeper mutations, addressing a major limitation of earlier drugs.

For patients, these advances could translate to more effective and safer cancer therapies targeting FGFR-driven tumors. The high selectivity for FGFR2/3 over FGFR1 is particularly significant, as it may reduce the risk of treatment-induced hyperphosphatemia, a common and sometimes dose-limiting side effect of current FGFR inhibitors. The ability to inhibit common resistance mutations means these next-generation drugs could offer durable responses where first-generation therapies fail. Early pharmacodynamic studies in animal models showed effective pathway inhibition without significant changes in serum phosphate, supporting the potential for improved tolerability in clinical settings.

Concept	Description	Key Reference
Gatekeeper Resistance	Mutations like FGFR2^V564F^ reduce inhibitor potency.	Shvartsbart et al.
PROTAC Degradation	Targeted FGFR2 degradation overcoming mutant resistance.	Hu et al.
Generative Chemistry	AI-driven scaffold design for FGFR2/3 selectivity.	Insilico Medicine
Dynamics-Based Design	Protein motion modeling yields FGFR2-specific inhibitors.	Palaniappan et al.
Covalent Inhibition	Irreversible FGFR2 engagement enhances potency.	Xie et al.
Clinical Translation	Selective inhibitors demonstrate improved safety and efficacy profiles.	Nakaki et al.